Mobile version
WeChat
Facebook
Twitter
Instagram
YouTube
App
Guangdong
Business
Baiyunshan Pharmaceutical boosts H1 R&D spending over 20% to fuel innovation
Baiyunshan generated 42.09 billion yuan ($5.96 billion) in operating revenue during the six-month period, marking a 0.61 percent year-on-year increase, according to the report. The company is listed in both Shanghai and Hong Kong.
2026-08-25 14:24:32
Baiyunshan Pharmaceutical boosts H1 R&D spending over 20% to fuel innovation

< Prev 1 ... 18 19 20